New JP Ultraviolet-Visible and Infrared Reference Spectra Published

In March 2023, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has published the "JP Drafts (March 2023) No.2". In this context, five new Ultraviolet-visible and Infrared reference spectra were published.

The following spectra were made available as PDF files:

• Aripiprazole
• Febuxostat
• Lornoxicam
• Oxaliplatin
• Tolvaptan

New monographs of these and for a few other APIs and tablets have also been published.

The comment period runs from 01 March to 31 May 2023. To submit remarks, a form for comments has to be downloaded and sent by e-mail to the authority after it has been filled in.